{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "25509363",
  "DateCompleted": {
    "Year": "2015",
    "Month": "01",
    "Day": "15"
  },
  "DateRevised": {
    "Year": "2022",
    "Month": "03",
    "Day": "16"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "eng"
    ],
    "ELocationID": [],
    "Journal": {
      "ISSN": "0019-1442",
      "JournalIssue": {
        "Volume": "67",
        "Issue": "7-8",
        "PubDate": {
          "Year": "2014",
          "Month": "Jul",
          "Day": "30"
        }
      },
      "Title": "Ideggyogyaszati szemle",
      "ISOAbbreviation": "Ideggyogy Sz"
    },
    "ArticleTitle": "Depression in Parkinson's disease.",
    "Pagination": {
      "StartPage": "229",
      "EndPage": "236",
      "MedlinePgn": "229-36"
    },
    "Abstract": {
      "AbstractText": [
        "The prevalence of major and minor depression in Parkinson's disease is around 30-40% but, unfortunately, depression remains frequently underrecognized and often undertreated. However, recognition and appropriate treatment of depression in patients with Parkinson's disease is essential for improving the cross-sectional picture and longitudinal course. This review focuses on the epidemiology, pathophysiology and different treatment modalities of depression in Parkinson's disease."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Rihmer",
        "ForeName": "Zolt\u00e1n",
        "Initials": "Z"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Gonda",
        "ForeName": "X\u00e9nia",
        "Initials": "X"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "D\u00f6me",
        "ForeName": "P\u00e9ter",
        "Initials": "P"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Research Support, Non-U.S. Gov't",
      "Review"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "Hungary",
    "MedlineTA": "Ideggyogy Sz",
    "NlmUniqueID": "17510500R",
    "ISSNLinking": "0019-1442"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Antidepressive Agents"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Antiparkinson Agents"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Antidepressive Agents"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Antiparkinson Agents"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Cognitive Behavioral Therapy"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Comorbidity"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Deep Brain Stimulation"
    },
    {
      "QualifierName": [
        "drug therapy",
        "epidemiology",
        "etiology",
        "physiopathology",
        "therapy"
      ],
      "DescriptorName": "Depression"
    },
    {
      "QualifierName": [
        "drug therapy",
        "epidemiology",
        "etiology",
        "physiopathology",
        "therapy"
      ],
      "DescriptorName": "Depressive Disorder, Major"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Electroconvulsive Therapy"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "drug therapy",
        "epidemiology",
        "psychology"
      ],
      "DescriptorName": "Parkinson Disease"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Prevalence"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Risk Factors"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Transcranial Magnetic Stimulation"
    }
  ]
}